Elsevier

The Lancet

Volume 357, Issue 9249, 6 January 2001, Pages 39-40
The Lancet

Research Letters
Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy

https://doi.org/10.1016/S0140-6736(00)03571-6Get rights and content

Summary

20–30% of gastric mucosa-associated lymphoid tissue (MALT) lymphoma associated with Helicobacter pylori do not regress after antibiotic therapy. Regression can be assessed only by extended follow-up. To assess whether t(11;18, q21;q21), which results in a chimeric transcript between the API2 and MLT genes, predicts lymphoma resistance to antibiotic therapy, we screened for the fusion transcript with RT-PCR in ten responsive and 12 non-responsive gastric MALT lymphomas. The API2-MLT transcript was detected in nine (75%) of 12 patients non-responsive to antibiotic therapy but not in responsive patients. Most H pylori-associated gastric MALT lymphomas that do not respond to antibiotic therapy are associated with t(11;18, q21;q21).

Cited by (401)

  • Comparison of high and low molecular weight chitosan as in-vitro boosting agent for photodynamic therapy against Helicobacter pylori using methylene blue and endoscopic light

    2019, Photodiagnosis and Photodynamic Therapy
    Citation Excerpt :

    Helicobacter pylori(H. pylori) in the stomach causes stomach cancer, chronic gastritis, and gastric ulcers. At present, the treatments for H. pylori infection are based on antibiotics and proton pump inhibitors, but the failure rate gradually increases because of the appearance of a resistant strain, intolerance to medication, or recurrent infection [1–5]. Therefore, another elimination method is needed to overcome these problems.

  • Non-Hodgkin Lymphomas

    2019, Abeloff’s Clinical Oncology
View all citing articles on Scopus
View full text